Characteristics of total cohort, 36 patients undergoing HSCT
| Clinical characteristics . | No. of patients with characteristic, stratified by PTDM status (percentage) . | P . | |
|---|---|---|---|
| No diabetes . | Diabetes . | ||
| Total no. of patients | 12 | 24 | |
| Age, y | |||
| Median | 45 | 43.5 | .545 |
| Range | 24-62 | 21-65 | |
| Sex | |||
| Male | 7 (58) | 10 (42) | .345 |
| Female | 5 (42) | 14 (58) | |
| Pretransplantation BMI, kg/m2 | |||
| Median | 27.6 | 26.2 | .159 |
| Range | 24.4-49.5 | 22.5-49.5 | |
| Pretransplantation HTN | |||
| Absent | 6 (50) | 17 (71) | .220 |
| Present | 6 (50) | 7 (29) | |
| Family history of DM | |||
| Absent | 3 (25) | 10 (42) | .326 |
| Present | 9 (75) | 14 (58) | |
| Pre-HCT laboratory data | |||
| Fasting glucose, mg/dL | |||
| Median | 95 | 97 | .545 |
| Range | 88-119 | 79-121 | |
| Fasting insulin, μU/mL | |||
| Median | 9.95 | 18.2 | .664 |
| Range | 6.7-109 | 1.60-194 | |
| Fasting C-peptide, ng/mL | |||
| Median | 2.95 | 5.95 | .307 |
| Range | 1.80-129 | 1.70-63.4 | |
| Transplantation characteristics | |||
| Diagnosis | |||
| AML + ALL | 7 (58) | 10 (42) | |
| CML | 3 (25) | 0 | |
| MDS + MPD | 1 (8) | 2 (8) | |
| NHL + HL | 1 (8) | 8 (33) | |
| Other malignancies | 0 | 4 (17) | |
| CIBMTR disease risk | |||
| Low/intermediate | 10 (83) | 17 (71) | .414 |
| High | 2 (17) | 7 (29) | |
| Conditioning regimen | |||
| Myeloablative | 8 (67) | 19 (79) | .414 |
| Reduced intensity | 4 (33) | 5 (21) | |
| Donor | |||
| Related | 9 (75) | 12 (50) | .151 |
| Unrelated | 3 (25) | 12 (50) | |
| Stem cell source | |||
| Peripheral blood | 10 (83) | 14 (58) | .134 |
| Other | 2 (17) | 10 (42) | |
| HLA | |||
| Matched | 11 (92) | 21 (88) | 1.00 |
| Mismatched | 1 (8) | 3 (12) | |
| Acute GVHD prophylaxis | |||
| CSA + methotrexate | 7 (58) | 17 (71) | .453 |
| CSA/FK506 + MMF | 5 (42) | 7 (29) | |
| Acute GVHD* | |||
| Grade 0 or 1 | 4 (33) | 4 (17) | .257 |
| Grade 2-4 | 8 (67) | 20 (83) | |
| GVHD organ involvement | |||
| Skin | 2 (17) | 14 (58) | .018 |
| Gastrointestinal | 7 (58) | 17 (71) | .453 |
| Liver | 0 | 0 | |
| Systemic steroids | |||
| Absent | 4 (33) | 4 (17) | .257 |
| Present | 8 (67) | 20 (83) | |
| Day 100 malignancy status | |||
| CR or PR | 11 (92) | 19 (79) | .640 |
| Relapse or progression | 1 (8) | 5 (21) | |
| Day 100 survival | |||
| Alive | 12 (100) | 22 (92) | .797 |
| Dead | 0 | 2 (8)† | |
| Clinical characteristics . | No. of patients with characteristic, stratified by PTDM status (percentage) . | P . | |
|---|---|---|---|
| No diabetes . | Diabetes . | ||
| Total no. of patients | 12 | 24 | |
| Age, y | |||
| Median | 45 | 43.5 | .545 |
| Range | 24-62 | 21-65 | |
| Sex | |||
| Male | 7 (58) | 10 (42) | .345 |
| Female | 5 (42) | 14 (58) | |
| Pretransplantation BMI, kg/m2 | |||
| Median | 27.6 | 26.2 | .159 |
| Range | 24.4-49.5 | 22.5-49.5 | |
| Pretransplantation HTN | |||
| Absent | 6 (50) | 17 (71) | .220 |
| Present | 6 (50) | 7 (29) | |
| Family history of DM | |||
| Absent | 3 (25) | 10 (42) | .326 |
| Present | 9 (75) | 14 (58) | |
| Pre-HCT laboratory data | |||
| Fasting glucose, mg/dL | |||
| Median | 95 | 97 | .545 |
| Range | 88-119 | 79-121 | |
| Fasting insulin, μU/mL | |||
| Median | 9.95 | 18.2 | .664 |
| Range | 6.7-109 | 1.60-194 | |
| Fasting C-peptide, ng/mL | |||
| Median | 2.95 | 5.95 | .307 |
| Range | 1.80-129 | 1.70-63.4 | |
| Transplantation characteristics | |||
| Diagnosis | |||
| AML + ALL | 7 (58) | 10 (42) | |
| CML | 3 (25) | 0 | |
| MDS + MPD | 1 (8) | 2 (8) | |
| NHL + HL | 1 (8) | 8 (33) | |
| Other malignancies | 0 | 4 (17) | |
| CIBMTR disease risk | |||
| Low/intermediate | 10 (83) | 17 (71) | .414 |
| High | 2 (17) | 7 (29) | |
| Conditioning regimen | |||
| Myeloablative | 8 (67) | 19 (79) | .414 |
| Reduced intensity | 4 (33) | 5 (21) | |
| Donor | |||
| Related | 9 (75) | 12 (50) | .151 |
| Unrelated | 3 (25) | 12 (50) | |
| Stem cell source | |||
| Peripheral blood | 10 (83) | 14 (58) | .134 |
| Other | 2 (17) | 10 (42) | |
| HLA | |||
| Matched | 11 (92) | 21 (88) | 1.00 |
| Mismatched | 1 (8) | 3 (12) | |
| Acute GVHD prophylaxis | |||
| CSA + methotrexate | 7 (58) | 17 (71) | .453 |
| CSA/FK506 + MMF | 5 (42) | 7 (29) | |
| Acute GVHD* | |||
| Grade 0 or 1 | 4 (33) | 4 (17) | .257 |
| Grade 2-4 | 8 (67) | 20 (83) | |
| GVHD organ involvement | |||
| Skin | 2 (17) | 14 (58) | .018 |
| Gastrointestinal | 7 (58) | 17 (71) | .453 |
| Liver | 0 | 0 | |
| Systemic steroids | |||
| Absent | 4 (33) | 4 (17) | .257 |
| Present | 8 (67) | 20 (83) | |
| Day 100 malignancy status | |||
| CR or PR | 11 (92) | 19 (79) | .640 |
| Relapse or progression | 1 (8) | 5 (21) | |
| Day 100 survival | |||
| Alive | 12 (100) | 22 (92) | .797 |
| Dead | 0 | 2 (8)† | |
BMI indicates body mass index; HTN, hypertension; DM, diabetes mellitus; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; MPD, myeloproliferative disorder; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; CIBMTR, Committee of International Bone Marrow Transplant Registry; CSA, cyclosporine; FK506, tacrolimus; MMF, mycophenolate mofetil; CR, complete response; and PR, partial response.
Grade of acute GVHD (0 or 1 vs 2-4) indicates maximal grade of acute GVHD during first 100 days of transplantation.
Causes of death included: relapse of malignancy (n = 1) and infection (n = 1).